Sutro Biopharma STRO Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| -$191.09M+16.0% | -$227.46M— | —— | -$119.2M-12.9% | ||
| $7.32M+1.5% | $7.22M+5.9% | $6.82M+19.8% | $5.69M+17.5% | ||
| $14.01M-43.3% | $24.69M-0.9% | $24.91M-5.3% | $26.3M+13.2% | ||
| $1.69M— | $0— | —— | —— | ||
| -$4.69M+84.0% | -$29.42M-202% | $28.96M+642% | -$5.34M-177% | ||
| —— | $706K-85.3% | $4.81M+493% | -$1.23M— | ||
| $1.74M— | —— | —— | —— | ||
| -$19.35M-263% | $11.86M— | —— | $3.54M— | ||
| -$571K+25.5% | -$766K-23.2% | -$622K— | —— | ||
| -$69.73M— | —— | —— | $99.49M+754% | ||
| -$7.48M-16.5% | -$6.42M-40.0% | -$4.59M-342% | $1.9M+170% | ||
| -$177.23M+11.8% | -$201M— | —— | —— | ||
| —— | —— | —— | —— | ||
| $45.01M-79.4% | $218.51M+5,669% | -$3.92M+88.8% | -$35.02M— | ||
| —— | —— | —— | —— | ||
| $0— | —— | $12.5M— | —— | ||
| $0— | —— | —— | $0-100% | ||
| $332K-34.8% | $509K+3.9% | $490K+5.8% | $463K— | ||
| —— | $94.08M— | —— | $48.31M+1,366% | ||
| -$134.08M-211% | $121.02M— | —— | —— | ||
| $75K-99.6% | $17.52M+4,523% | $379K— | $0-100% | ||
| $3.44M-64.7% | $9.72M+7.1% | $9.08M+2,393% | $364K+113% | ||
| $1.69M— | $0— | —— | —— | ||
| —— | -$7.35M-129% | $25.3M+286% | $6.56M+11.9% | ||
| $1.74M— | —— | —— | —— | ||
| -$7.48M-16.5% | -$6.42M-40.0% | -$4.59M-342% | $1.9M+170% | ||
| -$19.35M-263% | $11.86M— | —— | $3.54M— | ||
| $38.29M+23.2% | $31.07M+149% | $12.49M— | $0— | ||
| $5.88M+14.5% | $5.14M+41.6% | $3.63M+39.6% | $2.6M-47.3% | ||
| -$571K+25.5% | -$766K-23.2% | -$622K— | —— | ||
| $1.7M-45.3% | $3.1M-28.2% | $4.32M-45.1% | $7.86M-48.7% | ||
| $0-100% | $71.53M— | —— | —— | ||
| —— | —— | —— | —— | ||
| —— | —— | —— | —— | ||
| —— | —— | —— | —— | ||
| $3.41M-45.7% | $6.29M-36.1% | $9.84M— | —— | ||
| -$69.73M— | —— | —— | $99.49M+754% | ||
| -$7.48M-16.5% | -$6.42M-40.0% | -$4.59M-342% | $1.9M+170% | ||
| —— | —— | —— | —— | ||
| $75K-99.6% | $17.52M+4,523% | $379K— | $0-100% | ||
| -$177.24M+12.2% | -$201.76M— | —— | —— | ||
| -$177.24M+12.2% | -$201.76M— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Sutro Biopharma generate?
- Sutro Biopharma (STRO) generated -$151.6M in operating cash flow over the trailing twelve months.
- What is Sutro Biopharma's free cash flow?
- After $627.0K of capital expenditures, Sutro Biopharma's free cash flow was -$151.6M over the trailing twelve months, up 25.9% year over year.
- Where does Sutro Biopharma's cash flow data come from?
- Every line is extracted from Sutro Biopharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
